Impact of ribavirin dose reduction during treatment in chronic hepatitis C genotype 1 patients.
作者信息
Chung Woo Jin
出版信息
Clin Mol Hepatol. 2012 Sep;18(3):268-71. doi: 10.3350/cmh.2012.18.3.268. Epub 2012 Sep 25.
Abstract
摘要
相似文献
1
Impact of ribavirin dose reduction during treatment in chronic hepatitis C genotype 1 patients.
Clin Mol Hepatol. 2012 Sep;18(3):268-71. doi: 10.3350/cmh.2012.18.3.268. Epub 2012 Sep 25.
2
[Comparison of efficacy of peginterferon and ribavirin combination therapy for chronic hepatitis C among Korean, Caucasian and other Asians].
Korean J Gastroenterol. 2012 Nov;60(5):273-4. doi: 10.4166/kjg.2012.60.5.273.
3
Viral dynamics and prediction of response to treatment with pegylated interferon and ribavirin in patients with chronic hepatitis C.
Rev Esp Enferm Dig. 2009 Oct;101(10):665-70. doi: 10.4321/s1130-01082009001000001.
4
Is peginterferon and ribavirin therapy effective in Korean patients with chronic hepatitis C?
Clin Mol Hepatol. 2013 Mar;19(1):26-8. doi: 10.3350/cmh.2013.19.1.26. Epub 2013 Mar 25.
5
[Is 24 weeks of peginterferon and ribavirin combination therapy sufficient for the patients with genotype 1 chronic hepatitis C?].
Korean J Gastroenterol. 2010 Jul;56(1):59-61. doi: 10.4166/kjg.2010.56.1.59.
6
Commentary: efficacy and safety of ribavirin plus pegylated interferon-alpha in geriatric patients with chronic hepatitis C.
Aliment Pharmacol Ther. 2013 Feb;37(4):491. doi: 10.1111/apt.12175.
7
[Pegylated interferon α-2a and ribavirin antiviral therapy efficacy for treating chronic hepatitis C and its effects on psychological status of patients].
Zhonghua Gan Zang Bing Za Zhi. 2014 Oct;22(10):772-3.
8
The effect of alanine aminotransferase dynamics on predicting sustained virological response in chronic hepatitis C virus infection.
Korean J Hepatol. 2012 Mar;18(1):29-31. doi: 10.3350/kjhep.2012.18.1.29. Epub 2012 Mar 22.
9
[Chronic C virus infection management].
Rev Clin Esp. 2003 Sep;203(9):443-4. doi: 10.1157/13052564.
10
Ribavirin with interferon for hepatitis C in dialysis patients: efficacious and safe in the right patients in good hands.
Gut. 2015 Feb;64(2):190-1. doi: 10.1136/gutjnl-2014-307399. Epub 2014 May 26.
本文引用的文献
1
Impact of erythropoietin on sustained virological response to peginterferon and ribavirin therapy for HCV infection: a systematic review and meta-analysis.
J Viral Hepat. 2012 Feb;19(2):88-93. doi: 10.1111/j.1365-2893.2011.01532.x. Epub 2011 Oct 30.
2
Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate.
Gastroenterology. 2010 Nov;139(5):1602-11, 1611.e1. doi: 10.1053/j.gastro.2010.07.059. Epub 2010 Aug 16.
3
4
Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C.
Hepatology. 2008 May;47(5):1453-61. doi: 10.1002/hep.22217.
5
Anti-erythropoietin antibody-mediated pure red cell aplasia in a living donor liver transplant recipient treated for hepatitis C virus.
Liver Transpl. 2007 Nov;13(11):1589-92. doi: 10.1002/lt.21332.
6
Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update.
J Clin Oncol. 2008 Jan 1;26(1):132-49. doi: 10.1200/JCO.2007.14.3396. Epub 2007 Oct 22.
7
Early ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV/HCV co-infected patients during treatment with pegylated interferon and ribavirin.
J Hepatol. 2007 Jul;47(1):23-30. doi: 10.1016/j.jhep.2007.01.027. Epub 2007 Feb 22.
8
Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C.
Gastroenterology. 2007 Jan;132(1):103-12. doi: 10.1053/j.gastro.2006.11.011. Epub 2006 Nov 11.
9
Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment.
Clin Gastroenterol Hepatol. 2007 Jan;5(1):124-9. doi: 10.1016/j.cgh.2006.10.008. Epub 2006 Dec 28.
10
Erythropoietin treatment is associated with more severe thrombocytopenia in patients with chronic hepatitis C undergoing antiviral therapy.
Am J Gastroenterol. 2006 Oct;101(10):2275-82. doi: 10.1111/j.1572-0241.2006.00774.x.
Zotero 插件